Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) 9-valent recombinant vaccine (Hansenula polymorpha)
- Development stage
- Phase 3
- Lead developer
- Chongqing Bovax Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) 9-valent recombinant vaccine (Hansenula polymorpha) is a nonavalent prophylactic vaccine developed by Shanghai Bovax Biotechnology and its subsidiary Chongqing Bovax Biopharmaceutical. The vaccine is composed of recombinant virus-like particles (VLPs) of the major capsid protein L1 of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, expressed in the methylotrophic yeast *Hansenula polymorpha* and adsorbed onto an aluminum phosphate adjuvant. It is designed to prevent persistent infections and associated diseases caused by these nine HPV types, including cervical, vulvar, vaginal, anal, penile, and oropharyngeal cancers, as well as precancerous lesions (such as CIN, VIN, VaIN, AIN, and PIN) and genital warts. The vaccine is currently undergoing Phase III clinical trials in China for both male and female populations.
- Other names
- 9-valent HPV recombinant vaccine (Hansenula polymorpha)9-valent HPV vaccine (Hansenula polymorpha)9-valent recombinant HPV vaccine (Hansenula polymorpha)recombinant human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) nine-valent vaccine (Hansenula polymorpha)九价HPV疫苗（汉逊酵母）九价重组HPV疫苗（汉逊酵母）重组人乳头瘤病毒（6/11/16/18/31/33/45/52/58型）九价疫苗（汉逊酵母）
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV31 L1HPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)Human papillomavirus type 18 major capsid protein L1
Beyond the preview
Go deeper on human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) 9-valent recombinant vaccine (Hansenula polymorpha).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) 9-valent recombinant vaccine (Hansenula polymorpha).